Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R

Melanoma Research

Volumn 21, Issue 4, 2011, Pages 274-284

  Molhoek, Kerrington R ^a   Shada, Amber L ^a   Smolkin, Mark ^b   Chowbina, Sudhir ^c   Papin, Jason ^c   Brautigan, David L ^d   Slingluff, Craig L ^a  

^a Duke University Trent Drive   (United States)

^b Division of Biostatistics and Epidemiology   (United States)

^c Department of Biomedical Engineering ^*  (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

c Met; hepatocyte growth factor; hepatocyte growth factor receptor; insulin like growth factor 1; insulin like growth factor receptor 1; melanoma; receptor tyrosine kinases

Indexed keywords

B RAF KINASE; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MACROPHAGE STIMULATING PROTEIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PERVANADATE; PROTEIN TYROSINE KINASE; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 3;

ANTIBODY RESPONSE; ARTICLE; AUTOCRINE EFFECT; CELL LOSS; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA CELL; ONCOGENE N RAS; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPRODUCIBILITY; SIGNAL TRANSDUCTION;

AUTOCRINE COMMUNICATION; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LIGANDS; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RECEPTOR, IGF TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 79960708715     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328343a1d6     Document Type: Article

References (53)

1. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-3648. (Pubitemid 32786276)
2. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004; 10:1670-1677. (Pubitemid 38435557)
3. Lazar-Molnar E, Hegyesi H, Toth S, Falus A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000; 12:547-554. (Pubitemid 30453481)
4. Albino AP. The role of oncogenes and growth factors in progressive melanoma-genesis. Pigment Cell Res 1992; 5 (Suppl 2):199-218.
5. Shih IM, Herlyn M. Autocrine and paracrine roles for growth factors in melanoma. In Vivo 1994; 8:113-123. (Pubitemid 24156542)
6. Halaban R. Growth factors and melanomas. Semin Oncol 1996; 23:673-681.
7. Rodeck U, Herlyn M. Growth factors in melanoma. Cancer Metastasis Rev 1991; 10:89-101.
8. Molhoek KR, Griesemann H, Shu J, Gershenwald JE, Brautigan DL, Slingluff CL Jr. Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/ vascular endothelial growth factor receptor-2. Cancer Res 2008; 68:4392-4397.
9. Wang Y, Becker D. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med 1997; 3:887-893. (Pubitemid 27353449)
10. Halaban R, Langdon R, Birchall N, Cuono C, Baird A, Scott G, Moellmann G, McGuire J. Basic fibroblast growth factor from human keratinocytes is a natural mitogen for melanocytes. J Cell Biol 1988; 107:1611-1619.
11. Meier F, Nesbit M, Hsu MY, Martin B, Van Belle P, Elder DE, et al. Human melanoma progression in skin reconstructs: biological significance of b FGF. Am J Pathol 2000; 156:193-200. (Pubitemid 30644452)
12. Nesbit M, Nesbit HK, Bennett J, Andl T, Hsu MY, Dejesus E. Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes. Oncogene 1999; 18:6469-6476.
13. Shih IM, Herlyn M. Role of growth factors and their receptors in the development and progression of melanoma. J Invest Dermatol 1993; 100 (2 Suppl):196S-203S. (Pubitemid 23051698)
14. Hendrix MJ, Seftor EA, Seftor RE, Kirschmann DA, Gardner LM, Boldt HC, et al. Regulation of uveal melanoma interconverted phenotype by hepatocyte growth factor/scatter factor (HGF/SF). Am J Pathol 1998; 152:855-863. (Pubitemid 28173345)
15. Natali PG, Nicotra MR, Di Renzo MF, Prat M, Bigotti A, Cavaliere R, Comoglio PM. Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression. Br J Cancer 1993; 68:746-750. (Pubitemid 23301281)
16. Rusciano D, Lin S, Lorenzoni P, Casella N, Burger MM. Influence of hepatocyte growth factor/scatter factor on the metastatic phenotype of B16 melanoma cells. Tumour Biol 1998; 19:335-345. (Pubitemid 28384459)
17. Bellusci S, Moens G, Gaudino G, Comoglio P, Nakamura T, Thiery JP, Jouanneau J. Creation of an hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicity. Oncogene 1994; 9:1091-1099. (Pubitemid 24095017)
18. Tamatani T, Hattori K, Iyer A, Tamatani K, Oyasu R. Hepatocyte growth factor is an invasion/migration factor of rat urothelial carcinoma cells in vitro. Carcinogenesis 1999; 20:957-962. (Pubitemid 29263736)
19. Moriyama T, Kataoka H, Koono M, Wakisaka S. Expression of hepatocyte growth factor/scatter factor and its receptor c-Met in brain tumors: evidence for a role in progression of astrocytic tumors (review). Int J Mol Med 1999; 3:531-536.
20. Rong S, Bodescot M, Blair D, Dunn J, Nakamura T, Mizuno K, et al. Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol Cell Biol 1992; 12:5152-5158.
21. To CT, Tsao MS. The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers (review). Oncol Rep 1998; 5:1013-1024. (Pubitemid 28372555)
22. Vande Woude GF, Jeffers M, Cortner J, Alvord G, Tsarfaty I, Resau J. Met-HGF/SF: tumorigenesis, invasion and metastasis. Ciba Found Symp 1997; 212:119-130. [discussion 30-2, 48-54]
23. Li G, Schaider H, Satyamoorthy K, Hanakawa Y, Hashimoto K, Herlyn M. Downregulation of E-cadherin and desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene 2001; 20:8125-8135. (Pubitemid 34028337)
24. Molhoek KR, Brautigan DL, Slingluff CL Jr. Synergistic inhibition of human melanoma proliferation by combination treatment with B-raf inhibitor BAY43-9006 and m TOR inhibitor rapamycin. J Transl Med 2005; 3:39.
25. Yamshchikov GV, Mullins DW, Chang CC, Ogino T, Thompson L, Presley J, et al. Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. J Immunol 2005; 174:6863-6871. (Pubitemid 40705650)
26. Darrow TL, Slingluff CL Jr, Seigler HF. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. J Immunol 1989; 142:3329-3335. (Pubitemid 19129962)
27. Slingluff CL Jr, Colella TA, Thompson L, Graham DD, Skipper JC, Caldwell J, et al. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. Cancer Immunol Immunother 2000; 48:661-672. (Pubitemid 30146461)
28. Zhao Z, Tan Z, Diltz CD, You M, Fischer EH. Activation of mitogen-activated protein (MAP) kinase pathway by pervanadate, a potent inhibitor of tyrosine phosphatases. J Biol Chem 1996; 271:22251-22255. (Pubitemid 26303861)
29. Bennasroune A, Gardin A, Aunis D, Cremel G, Hubert P. Tyrosine kinase receptors as attractive targets of cancer therapy. Crit Rev Oncol Hematol 2004; 50:23-38. (Pubitemid 38501615)
30. Pegram M, Slamon D. Biological rationale for HER2/neu (c-erb B2) as a target for monoclonal antibody therapy. Semin Oncol 2000; 27 (5 Suppl 9):13-19.
31. Valentinis B, Baserga R. IGF-I receptor signalling in transformation and differentiation. Mol Pathol 2001; 54:133-137. (Pubitemid 32539602)
32. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997; 16:68-73. (Pubitemid 27198158)
33. Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev 2005; 16:441-467. (Pubitemid 41022013)
34. Chin L, Merlino G, De Pinho RA. Malignant melanoma: modern black plague and genetic black box. Genes Dev 1998; 12:3467-3481. (Pubitemid 28553239)
35. Yeh AH, Bohula EA, Macaulay VM. Human melanoma cells expressing V600E B-RAF are susceptible to IGF-1R targeting by small interfering RNAs. Oncogene 2006; 25:6574-6581. (Pubitemid 44646185)
36. Kanter-Lewensohn L, Dricu A, Wang M, Wejde J, Kiessling R, Larsson O. Expression of the insulin-like growth factor-1 receptor and its anti-apoptotic effect in malignant melanoma: a potential therapeutic target. Melanoma Res 1998; 8:389-397. (Pubitemid 28530790)
37. Li G, Satyamoorthy K, Meier F, Berking C, Bogenrieder T, Herlyn M. Function and regulation of melanoma-stromal fibroblast interactions: when seeds meet soil. Oncogene 2003; 22:3162-3171. (Pubitemid 36713768)
38. Maloney EK, McLaughlin JL, Dagdigian NE, Garrett LM, Connors KM, Zhou XM, et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003; 63:5073-5083. (Pubitemid 37022647)
39. Resnicoff M, Coppola D, Sell C, Rubin R, Ferrone S, Baserga R. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res 1994; 54:4848-4850. (Pubitemid 24289413)
40. Satyamoorthy K, Li G, Vaidya B, Kalabis J, Herlyn M. Insulin-like growth factor-I-induced migration of melanoma cells is mediated by interleukin-8 induction. Cell Growth Differ 2002; 13:87-93. (Pubitemid 34205516)
41. Satyamoorthy K, Li G, Vaidya B, Patel D, Herlyn M. Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and beta-catenin pathways. Cancer Res 2001; 61:7318-7324. (Pubitemid 32946531)
42. Halaban R, Rubin JS, Funasaka Y, Cobb M, Boulton T, Faletto D, et al. Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells. Oncogene 1992; 7:2195-2206.
43. Imokawa G, Yada Y, Morisaki N, Kimura M. Biological characterization of human fibroblast-derived mitogenic factors for human melanocytes. Biochem J 1998; 330 (Pt 3):1235-1239. (Pubitemid 28162000)
44. Matsumoto K, Tajima H, Nakamura T. Hepatocyte growth factor is a potent stimulator of human melanocyte DNA synthesis and growth. Biochem Biophys Res Commun 1991; 176:45-51.
45. Camp ER, Liu W, Fan F, Yang A, Somcio R, Ellis LM. RON, a tyrosine kinase receptor involved in tumor progression and metastasis. Ann Surg Oncol 2005; 12:273-281. (Pubitemid 40616491)
46. Danilkovitch-Miagkova A, Leonard EJ. Anti-apoptotic action of macrophage stimulating protein (MSP). Apoptosis 2001; 6:183-190. (Pubitemid 32423727)
47. Wagh PK, Peace BE, Waltz SE. Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. Adv Cancer Res 2008; 100:1-33. (Pubitemid 351942429)
48. Thomas RM, Toney K, Fenoglio-Preiser C, Revelo-Penafiel MP, Hingorani SR, Tuveson DA, et al. The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res 2007; 67:6075-6082. (Pubitemid 47037486)
49. Follenzi A, Bakovic S, Gual P, Stella MC, Longati P, Comoglio PM. Cross-talk between the protooncogenes Met and Ron. Oncogene 2000; 19:3041-3049.
50. Baselga J, Cortes J. Epidermal growth factor receptor pathway inhibitors. Cancer Chemother Biol Response Modif 2005; 22:205-223.
51. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792. (Pubitemid 32222155)
52. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005; 333:328-335. (Pubitemid 40848295)
53. Sihto H, Sarlomo-Rikala M, Tynninen O, Tanner M, Andersson LC, Franssila K, et al. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol 2005; 23:49-57. (Pubitemid 41702622)